The risk of SARS-CoV-2 outbreaks in low prevalence settings following the removal of travel restrictions

AUTHORS

R. Sachak-Patwa[1], H.M. Byrne[1], L. Dyson[2,3], R.N. Thompson[2,3,*]

*Correspondence to: robin.n.thompson@warwick.ac.uk

AFFILIATIONS

[1]Mathematical Institute, University of Oxford, Oxford, UK

[2]Mathematics Institute, University of Warwick, Coventry, UK

[3]Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, University of Warwick, Coventry, UK

ABSTRACT

Countries around the world have introduced travel restrictions to reduce SARS-CoV-2 transmission. As vaccines are gradually rolled out, attention has turned to when travel restrictions and other non-pharmaceutical interventions (NPIs) can be relaxed. Here, using SARS-CoV-2 as a case study, we develop a mathematical branching process model to assess the risk that, following the removal of NPIs, cases introduced into new locations initiate a local outbreak. Our model accounts for changes in background population immunity due to vaccination. We consider two locations in which the vaccine rollout has progressed quickly – specifically, the Isle of Man (a British crown dependency in the Irish Sea) and the country of Israel. We show that the outbreak risk

is unlikely to be eliminated completely when travel restrictions and other NPIs are removed, even once the vaccine programmes in these locations are complete. Specifically, the risk that an imported case initiates an outbreak following the vaccine rollout and removal of NPIs is projected to be 0.373 (0.223,0.477) for the Isle of Man and 0.506 (0.387,0.588) for Israel. Key factors underlying these risks are the potential for transmission even following vaccination, incomplete vaccine uptake, and the recent emergence of SARS-CoV-2 variants with increased transmissibility. Combined, these factors suggest that when travel restrictions are relaxed, it will still be necessary to implement surveillance of incoming passengers to identify infected individuals quickly. This measure, as well as tracing and isolating contacts of detected infected passengers, should remain in place to suppress potential outbreaks until case numbers globally are reduced.

KEYWORDS

mathematical modelling; infectious disease epidemiology; outbreaks; non-pharmaceutical interventions; travel restrictions

1. INTRODUCTION

Combinations of non-pharmaceutical interventions (NPIs) have been introduced worldwide to counter the COVID-19 pandemic [1–3]. These measures include travel restrictions [4,5] and a range of other NPIs intended to reduce the numbers of contacts

between individuals [6]. The development and deployment of vaccines has also lowered transmission [7–10] and reduced the number of individuals experiencing clinical symptoms or severe disease once infected [11–13].

Effective NPIs have led to low levels of transmission in some locations. Australia and New Zealand have often been cited as examples of countries that have implemented NPIs effectively, with travel restrictions and quarantine of inbound travellers combined with short-term lockdowns and contact tracing to identify infected contacts whenever cases have been discovered [14–16]. At the time of writing (1st May 2021), Israel is the country that has vaccinated the largest proportion of its citizens, and the vaccination campaign there has been credited with reducing transmission [8], prompting some NPIs to be removed.

Despite the success of both NPIs and vaccines, the current overall picture is complicated. Vaccines do not prevent transmission entirely [7,17,18], and vaccine uptake is incomplete, particularly in some ethnic groups and in underserved communities [19]. Current tentative estimates suggest that first doses of the Pfizer and AstraZeneca SARS-CoV-2 vaccines are around 60% effective at preventing infection, with the second doses leading to 65-85% efficacy against infection [17]. Furthermore, the appearance of novel SARS-CoV-2 variants makes eliminating transmission more challenging. For example, the B.1.1.7 variant (VOC 202012/01) that first appeared in the United Kingdom in late 2020 has been found to be more transmissible than the SARS-CoV-2 virus that originally emerged in China [20]. Although public health

measures have had some successes, these concerns raise a key question: Can NPIs such as travel restrictions be removed without any risk in low prevalence settings where vaccines have been distributed widely, or might outbreaks occur initiated by SARS-CoV-2 reimportations from elsewhere?

Epidemiological models are often used to assess the risk of outbreaks in scenarios in which the potential for pathogen transmission is not changing. According to the mathematical theory of branching processes, the probability that cases introduced into a new host population generate an outbreak driven by sustained local transmission is given by

$$\mathrm{Prob(outbreak)} = 1 - \left(\frac{1}{R}\right)^{I_0}, \qquad (1)$$

in which R is the reproduction number of the pathogen and I_0 is the number of introduced infectious cases. This expression had been used to assess the risks of outbreaks of pathogen including the Ebola virus [21–23], before being applied early in the COVID-19 pandemic to assess outbreak risks outside China [24]. Equation (1) reflects the risk that introduced cases generate an outbreak, however it involves an assumption that pathogen transmissibility is fixed at its current level. In other words, the value of R is implicitly assumed to remain constant over the initial phase of the potential outbreak. With a background of rapidly changing population immunity due to vaccination acting to reduce transmission, this assumption may not be accurate. To assess the risk of outbreaks if NPIs are removed during an ongoing vaccination campaign using branching process models, standard epidemiological modelling theory must be extended to account for temporally changing population immunity.

Here, we use branching processes to investigate whether or not an introduced case initiates an outbreak, accounting fully for temporal changes in population immunity due to an ongoing vaccination campaign. We use four metrics to assess the risk of an outbreak and consider two examples of vaccination campaigns from around the world, from the Isle of Man and the country of Israel. In both locations, vaccination is progressing quickly and prevalence is currently low. Given the relatively low numbers of cases in these locations during the pandemic, there is also likely to be a background of limited immunity from previous infections. We assess the risk of outbreaks in these places when travel restrictions and other NPIs are removed, considering scenarios in which NPIs are removed at different stages of the vaccination campaigns. Crucially, even when all vaccines have been deployed in those locations, we project that the combination of incomplete vaccine uptake, imperfect vaccination and variants of concern mean that the risk of outbreaks due to imported cases will not be eliminated completely when NPIs are removed. This highlights the need for careful monitoring of imported cases until global prevalence is reduced to low levels. Until vaccines are rolled out worldwide, there is still a risk of local transmission arising in low prevalence settings initiated by importations from elsewhere.

2. METHODS

<u>Epidemiological model</u>

We performed our analyses using a stochastic branching process model that describes virus transmission in the initial stages of a potential outbreak. In the model, following the arrival of a case in the local population, new infections occur at rate $\beta(1-\Lambda(t))$ and infected individuals have a mean infectious period of $1/\mu$ days (Fig 1a). The function $\Lambda(t)$ reflects the extent to which transmission has been reduced by vaccination, where a value of $\Lambda(t)=0$ corresponds to an entirely unvaccinated population.

To model an ongoing vaccination campaign, we set $\Lambda(t)=\eta_1 V_1(t-\alpha)+\eta_2 V_2(t-\alpha)$, where $V_1(t)$ is the proportion of individuals in the population who have received a single vaccine dose at time t and $V_2(t)$ is the proportion of individuals in the population who have received two vaccine doses at time t (Fig 1b). The parameters η_1 and η_2 reflect the effectiveness of the vaccine at preventing infection after one and two effective doses, respectively (specifically, η_1 and η_2 represent the multiplicative reduction in susceptibility following one or two effective doses, compared to an unvaccinated individual, so that $0 \leq \eta_1 \leq \eta_2 \leq 1$), and the parameter α represents the delay between a vaccine dose being administered and being effective in the recipient. In our main analyses, since we are modelling relatively low prevalence settings, we do not consider immunity due to prior infections, although we present a supplementary analysis in which we considered the robustness of our results to this assumption.

Under this model, the time-dependent reproduction number, accounting for any vaccines that have been administered and are effective at time t, is given by

$$R_V(t)=\frac{\beta(1-\Lambda(t))}{\mu}. \qquad (2)$$

The value of $R_V(t)$ represents the expected number of secondary infections generated by a single infected individual in the population at time t, under the assumption that no further vaccinations take place in future. It is therefore representative of the "instantaneous" transmissibility at time t. Indeed, $R_V(t)$ is sometimes referred to as the instantaneous reproduction number [25–27]. In the absence of vaccination, so that $\Lambda(t) = 0$, then $R_V(t)$ is equal to the basic reproduction number, R_0.



Figure 1. The epidemiological model used in our analysis. (a) Following the introduction of an infected individual into the host population, local transmission may happen with infections occurring at rate $\beta(1 - \Lambda(t))$, where $\Lambda(t)$ reflects the vaccination coverage in the local population. Infected individuals have mean

infectious period $1/\mu$ days. (b) The vaccination process is modelled by setting $\Lambda(t)$ according to the proportion of individuals in the population who have been vaccinated with one (V_1) or two (V_2) doses. The first vaccine dose is assumed to have effectiveness η_1 and the second vaccine dose has effectiveness η_2, where the values of η_1 and η_2 are the multiplicative reductions in the susceptibility of individuals who have been vaccinated with one or two vaccine doses, respectively (compared to an unvaccinated host). Vaccine doses are effective α days after they are administered. This leads to declining population susceptibility as a vaccine is rolled out across the population.

Vaccination data

In the model, $V_1(t)$ and $V_2(t)$ were set based on vaccination data from the location under consideration (either the Isle of Man or Israel). Data describing the proportion of the total population who had received one or two vaccine doses were available for the periods up until 11th April 2021 (for the Isle of Man [28]) and 21st April 2021 (for Israel [29]).

To explore how the risk of outbreaks is likely to change in future, we projected the vaccine rollout forwards beyond these dates in the following way. We considered the total population size of the location under consideration (denoted N), as well as the numbers of individuals ($N_1(t)$ and $N_2(t)$) vaccinated with one or two doses, so that $V_1(t) = N_1(t)/N$ and $V_2(t) = N_2(t)/N$. We assumed that a constant number of vaccine doses are available each day in future (denoted D), and that there is a target period of τ days between each vaccine dose. On any day in future, each available dose is assigned

to an individual who has been vaccinated with their first dose at least τ days ago, with remaining doses then assigned to unvaccinated individuals. Resulting values of $N_1(t)$ and $N_2(t)$ were then converted to corresponding values of $V_1(t)$ and $V_2(t)$. To reflect the fact that vaccine uptake is imperfect, we assumed that a maximum proportion ν of the population can ever be vaccinated. Consequently, once the vaccination programme is complete, then $\Lambda(t) = \eta_2 \nu$. Since there is uncertainty in the vaccine uptake going forwards, we conducted supplementary analyses in which we considered a range of different values of ν. Values of the model parameters used in the analyses in the main text for the Isle of Man and Israel are shown in Table 1.

Outbreak risk metrics

We used four different metrics to assess the risk that an infected individual, introduced into the population at time t, initiates an outbreak driven by sustained local transmission. The values of each of these metrics vary temporally. An overview of these metrics is provided here; additional details are available in the Supplementary Information.

The first metric we considered is the *Instantaneous Outbreak Risk (IOR)*. This quantity represents the expression shown in equation (1), with $R = R_V(t)$ and $I_0 = 1$. The IOR reflects the risk of an outbreak occurring starting from a single infected individual at time t, but under the assumption that the vaccine rollout does not continue after time t so that pathogen transmissibility is unchanged. While the IOR straightforward to calculate,

it does not reflect changing population immunity due to vaccination over the initial phase of the potential outbreak. This standard metric is often used to assess the risk of outbreaks in scenarios where pathogen transmissibility does not vary temporally [21–24,30–32].

The second metric is the *Case Outbreak Risk (COR)*. The COR is an extension of the IOR, accounting for changes in population susceptibility due to vaccination over the initial phase of the potential outbreak. The COR has previously been used to assess outbreak risks using branching processes for models in which pathogen transmission varies periodically [30,33–35]. Its calculation involves solving the differential equation

$$\frac{dq(t)}{dt} = \beta(1 - \Lambda(t))q(t)\big(1 - q(t)\big) + \mu(q(t) - 1). \qquad (3)$$

The COR at time t is then given by $1 - q(t)$. Further details, including the derivation of equation (3), are provided in the Supplementary Information.

The third metric we considered is the *Simulated Outbreak Risk (SOR)*. The SOR involves repeated simulation of the branching process model, using the direct version of the Gillespie stochastic simulation algorithm [36] adapted to account for temporally varying pathogen transmissibility. Simulations were run starting with a single infected individual introduced into the population at time t. The SOR then corresponds to the proportion of simulations in which a local outbreak occurs; an outbreak is said to occur if the total number of individuals infected simultaneously exceeds a pre-defined threshold value, M. In our analyses, we set $M = 100$.

Finally, we consider the *Numerical Outbreak Risk (NOR)*. The NOR is analogous to the SOR, but with the advantage that it does not require large numbers of model simulations to be run. The NOR, therefore, also represents the risk that a single infected individual introduced into the population at time t initiates an outbreak in which at least $M = 100$ individuals are ever infected simultaneously.

Table 1: Default parameter values used in our analyses.

Parameter	Description	Value	Source
β	Transmission rate parameter	Set so that $R_0 = \frac{\beta}{\mu}$ takes a prescribed value	Two scenarios were considered, with median R_0 values of 3 (sim. to original SARS-CoV-2 variant [37]) and 5 (sim. to novel variant B.1.1.7 [20])
$1/\mu$	Duration of infectiousness	5 days	[38]
α	Delay between a vaccine dose being administered and being effective	14 days	[39]
η_1	Multiplicative reduction in susceptibility of an individual vaccinated with a single effective dose (compared to an unvaccinated host)	0.6	[17]
η_2	Multiplicative reduction in susceptibility of an individual vaccinated with two effective doses (compared to an unvaccinated host)	0.85	[17]
ν	Vaccine uptake	0.8 (Isle of Man) and 0.7 (Israel). Other values are considered in the Supplementary Information	[40]
N	Total population size	85,400 (Isle of Man) and 8,772,800 (Israel)	[41]
D	Number of vaccine doses available each day (in future projections)	1,000 (Isle of Man) and 56,000 (Israel)	Average number of doses administered each day in the previous 30 days (up to 11 April 2021 for Isle of

			Man [28] and 21 April 2021 for Israel [29])
τ	Target period between vaccine doses (in future projections)	84 days (Isle of Man) and 21 days (Israel)	[42,43]

3. RESULTS

As described in the Methods, we first generated projections of the number of vaccinated individuals in future for the Isle of Man (Fig 2a) and Israel (Fig 2d), based on past vaccination data in those locations. To explore the impact of vaccination on virus transmission, we calculated the time-dependent reproduction number ($R_V(t)$; equation (2)) throughout the vaccination campaign. We considered two different scenarios. In the first, we set the median value of R_0 (i.e., the reproduction number in the absence of vaccination) equal to 3, as was the situation early in the COVID-19 pandemic (Fig 2b,e). In the second scenario, we set the median value of R_0 equal to 5 (Fig 2c,f) to reflect the fact that currently circulating SARS-CoV-2 variants are more transmissible than the original virus [20]. This second scenario is therefore likely to be a more realistic reflection of the current and future risk.



Figure 2. Effect of vaccination on population susceptibility. (a) The proportion of the population of the Isle of Man who are unvaccinated $(1 - V_1(t) - V_2(t))$, vaccinated with a single dose $(V_1(t))$ and vaccinated with two doses $(V_2(t))$. The period in which vaccination data were available is shown in white, and the period in which vaccination data were projected is shown in purple. (b) The time-dependent reproduction number $(R_V(t))$ corresponding to the vaccination data in panel a, starting from a median initial value of $R_V(0) = R_0 = 3$. To account for uncertainty in the value of R_0, a normal distribution was assumed about the median value of R_0 with variance $\sigma^2 = 0.25$, which is reflective of the range of R_0 values estimated early in the COVID-19 pandemic [37]. (c) Analogous to panel b but starting from a median initial value of $R_V(0) = R_0 = 5$. (d)-(f) Analogous to panels a-c but using vaccination data for Israel. In all panels, $t = 0$ days corresponds to 18th December 2020. Ticks on the x-axes refer to the starts of the months labelled. Parameter values are shown in Table 1.

We then calculated the values of the four different outbreak risk metrics throughout the period considered (18th December 2020 to 20th August 2021) based on these vaccination projections (Fig 3). This involves a scenario in which NPIs are removed

entirely, so that $R_V(t)$ is not reduced by interventions other than vaccination. These metrics then reflect the risk that a single case first entering into the population at the date of introduction shown initiates an outbreak driven by sustained local transmission, given that no NPIs are in place. For each metric, and each time during the vaccination programme, we calculated the outbreak risk by integrating over the full distribution for $R_V(t)$ shown in Fig 2. The resulting outbreak risk therefore represents a point estimate of the risk accounting for uncertainty in pathogen transmissibility.

The IOR represents the probability of sustained local transmission based only on the value of $R_V(t)$ at the precise instance that the virus is introduced into the population. When an introduction occurs while a vaccine is being deployed, there is a background of decreasing population susceptibility, and so $R_V(t)$ may in fact decrease over the initial stages of a potential outbreak. For that reason, it is unsurprising that the IOR sometimes overestimates the outbreak risk compared to the other risk metrics (see e.g. black lines in Fig 3a,c – and see Discussion).

In contrast, we found close agreement between the COR, SOR and NOR. Due to the high assumed vaccine uptake in the Isle of Man, the outbreak risk at the end of the vaccination programme there was calculated to be lower than when the vaccine rollout was completed in Israel (although we also considered supplementary analyses with different assumed vaccine uptake values – Fig S1). In the first scenario that we considered (median $R_0 = 3$), which is representative of the transmissibility of the original

SARS-CoV-2 virus, the outbreak risk was projected to be low following the vaccination programme in the Isle of Man.

However, when the virus was assumed to be more transmissible (median $R_0 = 5$), as is the case for newly emerged variants of concern such as B.1.1.7, the outbreak risk was found to be substantial even following the projected end of the vaccination campaigns in both the Isle of Man and Israel. For example, when the assumed vaccine uptake values of $\nu = 0.8$ and $\nu = 0.7$ had been achieved in the Isle of Man and Israel, respectively, the NOR took values of 0.373 (95% credible interval [0.223,0.477] calculating using the 95% credible interval for $R_V(t)$ at the end of the vaccination rollout) and 0.506 ([0.387,0.588]) in those locations.



Figure 3. The risk that an infectious case introduced at each stage of the vaccination campaign initiates an outbreak, if travel restrictions and other NPIs are removed. (a) The outbreak risk assessed using the four metrics (IOR – black; COR – blue dashed; SOR – green dots; NOR – red), based on vaccination data from the Isle of Man and assuming $R_0 = 3$, as in Fig 2b. The period in which vaccination data were available is shown in white, and the period in which vaccination data were projected is shown in purple. (b) Analogous to panel b but with $R_0 = 5$ (see Fig 2c). (c) Analogous to panel a but using vaccination data for Israel (see Fig 2e). (d). Analogous to panel a but using vaccination data for Israel with $R_0 = 5$ (see Fig 2f). Ticks on the x-axes refer to the starts of the months labelled. Parameter values are shown in Table 1.

306 ## 4. DISCUSSION

307

308 As vaccines are administered in countries around the world, attention has turned to the
309 possibility that transmission will soon be reduced to the extent that travel restrictions
310 and other NPIs can be relaxed. Here, we have investigated the impact of removing NPIs
311 on the risk of outbreaks occurring in locations with low prevalence and a significant
312 proportion of the population vaccinated. We used four metrics to quantify the risk that a
313 case introduced at any stage in the vaccination rollout leads to an outbreak driven by
314 local transmission, in a scenario in which NPIs are removed. We calculated temporal
315 changes in the values of these metrics in the context of vaccination in the Isle of Man
316 and in Israel, two locations with low prevalence and vaccination campaigns that have
317 progressed quickly.

318

319 We found that vaccination is leading to a substantial drop in the potential for virus
320 transmission in both the Isle of Man and Israel, as indicated by a decreasing value of
321 the time-dependent reproduction number, $R_V(t)$ (Fig 2). However, even when the
322 vaccine rollout is completed, a combination of vaccines not preventing transmission
323 entirely, incomplete vaccine uptake and the emergence of novel SARS-CoV-2 variants
324 suggests that the risk of outbreaks initiated by infected individuals arriving from
325 elsewhere will not be eliminated when NPIs are removed (Fig 3). This conclusion
326 remained true unless the vaccine uptake was very high (Fig S1). This suggests that,
327 when NPIs such as travel restrictions are relaxed, it will still be advisable to be aware of
328 the potential for local transmission. Ensuring that case numbers are reduced elsewhere

329 (i.e., in locations that imported cases might travel from) will reduce the risk of
330 importations, and strategies should be considered to suppress local outbreaks quickly if
331 importations occur.
332
333 One potential use of our modelling framework by policy-makers is to identify the dates
334 on which travel restrictions can be relaxed, based on a maximum acceptable outbreak
335 risk. As an example, if the maximum acceptable value of the NOR is 0.4, then our
336 analysis with $R_0 = 5$ suggests that travel restrictions can be lifted on the Isle of Man at
337 the end of July 2021 (Fig 3b; the first date on which the NOR falls below 0.4 is 29th July
338 2021). However, as described above, since the risk of local transmission following
339 introductions remains, it will be necessary to continue to monitor inbound passengers in
340 low prevalence settings to identify infected individuals, even once vaccine programmes
341 are complete.
342
343 Our modelling approach for assessing outbreak risks was motivated by studies in which
344 the potential for pathogen transmission varies periodically [30,33–35,44–47], due, for
345 example, to seasonal changes in weather conditions that affect transmission. In that
346 context, Carmona and Gandon [33] describe a “winter is coming effect”, in which the
347 risk of an outbreak is lower than current environmental conditions suggest if conditions
348 become less favourable for transmission in the near future. In the terminology used in
349 our manuscript, if current environmental conditions promote pathogen transmission,
350 then the IOR is expected to be high. This is because the IOR reflects the outbreak risk
351 based on the conditions at the precise instance when the virus is introduced into the

population. However, if environmental conditions are expected to become less favourable for transmission in the near future, then the values of the other risk metrics are lower than the IOR, since those metrics account for changes in transmissibility over the initial phase of the potential outbreak. Although in general we found a close agreement between the four metrics that we considered, a background of decreasing population susceptibility can lead to a similar effect in which the IOR is larger than the COR, SOR or NOR (e.g. Fig 3a,c).

In this study, we used a simple branching process model to investigate the risk of outbreaks when NPIs are removed during a vaccination programme. This involved considering whether introduced cases are likely to lead to sustained local transmission or instead fade out without causing an outbreak. We made the standard branching process modelling assumption that population immunity is unaffected by infections in the earliest stages of potential outbreaks [21–24,48,49]. In other words, infection-acquired immunity following the arrival of the pathogen in the host population is not considered. While this is reasonable when case numbers are low in the initial stages of potential outbreaks, a more detailed model is needed to explore other quantities, such as the eventual size of outbreaks. Following a vaccination programme, outbreaks are likely to be smaller than those that occur before vaccines are widely administered.

Another simplification of our model is that we only accounted for changes in population susceptibility due to the vaccine rollout. We did not account for prior immunity of some members of the population due to previous exposures to the virus. At the time of writing

375 (1st May 2021), there have been 1,154 confirmed cases in the Isle of Man and 838,000
376 confirmed cases in Israel. Since these case numbers correspond to a relatively small
377 proportion of the host population (representing 1.35% and 9.55% of the population in
378 the Isle of Man and Israel, respectively), we do not expect this assumption to affect our
379 key findings. Furthermore, immunity is likely to wane over time [50,51], reducing the
380 effect of previous exposures on the outbreak risk. To test the potential impact of
381 infection-induced immunity arising from cases occurring before May 2021, we also
382 conducted a supplementary analysis in which the value of R_0 is reduced by 1.35% in the
383 Isle of Man and 9.55% in Israel, and we found qualitatively similar results (Fig S2): even
384 in this "best case" scenario, there is still a risk of outbreaks due to imported cases once
385 the vaccination programmes are completed. Importantly, in other countries in which
386 higher numbers of cases have occurred, prior immunity may play a larger role in
387 reducing the risk of outbreaks compared to the low prevalence settings considered
388 here. Understanding the extent of this effect, based on the rate at which immunity
389 wanes, is an important target for further study.
390
391 In this research, we assumed that vaccines reduce transmission by lowering the
392 probability that a vaccinated host becomes infected compared to an unvaccinated host.
393 In reality, vaccination can reduce the probability of infection as assumed here [52],
394 reduce the risk of onwards transmission following infection [7], reduce the risk of severe
395 disease developing, or a combination of these effects [53]. In principle, it would be
396 possible to develop a more complex model that accounts for each of these effects. It
397 would also be possible to include other factors affecting transmission and vaccination,

for example the impact of population-structure on both vaccine efficacy [54] and transmission [55,56], or the possibility that individuals' behaviour may be different following the pandemic compared to beforehand, even when NPIs and travel restrictions are removed. For precise quantitative outbreak risk predictions to be made, it may be necessary to estimate R_0 in different locations. The value of R_0 might be expected to differ between countries, and inference of pathogen transmissibility in low prevalence settings where only limited case notification data are available is an important challenge [57,58].

Despite its simplicity, our modelling approach has demonstrated the general principle that, even following complete vaccination programmes in low prevalence settings, the risk of outbreaks remains when NPIs are removed. Our intention is not to argue that travel restrictions and other NPIs should not be relaxed once vaccination programmes are sufficiently advanced, but rather that measures should be taken to ensure that any clusters of cases are suppressed quickly if they arise. A local outbreak requires two steps: first, the virus must be imported from elsewhere; second, local transmission must occur. The first step emphasises the need for a global approach to minimising transmission, since large case numbers at a potential source location translates into a higher importation risk. The second step emphasises the need to ensure that, while vaccination acts to reduce transmission substantially, continued surveillance of inbound passengers for infection, combined with isolation and testing of contacts of detected infected individuals, is important when travel restrictions and other NPIs are relaxed. These measures are necessary, since only once the global prevalence of SARS-CoV-2

infections is reduced substantially can the risk of outbreaks in low prevalence settings be eliminated.

COMPETING INTERESTS

We have no competing interests.

DATA ACCESSIBILITY

All data required to reproduce the results presented here are available at https://github.com/robin-thompson/Outbreaks_Low_Prevalence_Settings/. Raw data are also shown in Figs 2a and 2d. No restrictions exist on data availability.

CODE AVAILABILITY STATEMENT

All code required to reproduce the results presented here are available at https://github.com/robin-thompson/Outbreaks_Low_Prevalence_Settings/, along with relevant documentation.

AUTHORS' CONTRIBUTIONS

Conceptualization: RS-P, RNT, LD; Methodology: RS-P, RNT; Investigation: RS-P; Supervision: RNT, HMB; Writing – original draft: RNT, RS-P; Writing – review and editing: All authors.

FUNDING

RS-P is supported by the EPSRC through the Centre for Doctoral Training in Industrially Focussed Mathematical Modelling at the University of Oxford (grant EP/L015803/1), in collaboration with Biosensors Beyond Borders Ltd. LD was supported by the MRC through the COVID-19 Rapid Response Rolling Call (grant MR/V009761/1) and by UKRI through the JUNIPER modelling consortium (grant MR/V038613/1). The funders had no role in study design, data collection and analysis, preparation of the manuscript or the decision to publish.

ACKNOWLEDGEMENTS

We thank members of the Wolfson Centre for Mathematical Biology (University of Oxford) and the Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research (University of Warwick) for helpful discussions about this work.

REFERENCES

1. Liu Y, Morgenstern C, Kelly J, Lowe R, Jit M. The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories. BMC Med. 2021;19: 40.
2. Leung K, Wu JT, Liu D, Leung GM. First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. Lancet. 2020;395: 1382–1393.
3. Cowling BJ, Ali ST, Ng TWY, Tsang TK, Li JCM, Fong MW, et al. Impact

466 assessment of non-pharmaceutical interventions against coronavirus disease
467 2019 and influenza in Hong Kong: an observational study. Lancet Public Heal.
468 2020;4: 397–404.
469 4. Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, et al. The
470 effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-
471 19) outbreak. Science (80-). 2020;368: 395–400.
472 5. Daon Y, Thompson RN, Obolski U. Estimating COVID-19 outbreak risk through
473 air travel. J Travel Med. 2020;27: taaa093.
474 6. Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, et al. The effect of
475 control strategies to reduce social mixing on outcomes of the COVID-19 epidemic
476 in Wuhan, China: a modelling study. Lancet Public Heal. 2020;5: e261–e270.
477 7. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Impact of
478 vaccination on household transmission of SARS-COV-2 in England. medRxiv.
479 2021.
480 8. Rossman H, Shilo S, Meir T, Gorfine M, Shalit U, Segal E. COVID-19 dynamics
481 after a national immunization program in Israel. Nat Med. 2021.
482 9. Shah AS, Gribben C, Bishop J, Hanlon P, Caldwell D, Wood R, et al. Effect of
483 vaccination on transmission of COVID-19: an observational study in healthcare
484 workers and their households. medRxiv. 2021.
485 10. Richterman A, Meyerowitz EA, Cevik M. Indirect protection by reducing
486 transmission: Ending the pandemic with SARS-CoV-2 vaccination. Open Forum
487 Infect Dis. 2021; ofab259.
488 11. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety

489 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383.
490 12. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al.
491 Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-
492 CoV-2: an interim analysis of four randomised controlled trials in Brazil, South
493 Africa, and the UK. Lancet. 2021;397.
494 13. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and
495 Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384.
496 14. Baker MG, Wilson N, Blakely T. Elimination could be the optimal response
497 strategy for covid-19 and other emerging pandemic diseases. BMJ. 2020;371.
498 15. Huang QS, Wood T, Jelley L, Jennings T, Jefferies S, Daniells K, et al. Impact of
499 the COVID-19 nonpharmaceutical interventions on influenza and other respiratory
500 viral infections in New Zealand. Nat Commun. 2021;12.
501 16. Baker MG, Wilson N, Anglemyer A. Successful elimination of Covid-19
502 transmission in New Zealand. N Engl J Med. 2020;383.
503 17. Keeling MJ, Moore S, Dyson L, Tildesley MJ, Hill EM. Road map scenarios and
504 sensitivity. 2021. Available:
505 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/atta
506 chment_data/file/975911/S1184_SPI-
507 M_University_of_Warwick_Road_Map_Scenarios_and_Sensitivity.pdf
508 18. Moore S, Hill EM, Tildesley MJ, Dyson L, Keeling MJ. Vaccination and non-
509 pharmaceutical interventions for COVID-19: a mathematical modelling study.
510 Lancet Infect Dis. 2021;S1473-3099: 00143–2.
511 19. Razai MS, Osama T, McKechnie DGJ, Majeed A. Covid-19 vaccine hesitancy

512 among ethnic minority groups. BMJ. 2021.
513 20. Davies N, Abbott S, Barnard R, Jarvis C, Kucharski A, Munday J, et al. Estimated
514 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science
515 (80-). 2021.
516 21. Althaus CL, Low N, Musa EO, Shuaib F, Gsteiger. Ebola virus disease outbreak
517 in Nigeria: Transmission dynamics and rapid control. Epidemics. 2015;11: 80–84.
518 22. Thompson RN, Gilligan CA, Cunniffe NJ. Detecting presymptomatic infection is
519 necessary to forecast major epidemics in the earliest stages of infectious disease
520 outbreaks. PLoS Comput Biol. 2016;12: e1004836.
521 23. Merler S, Ajelli M, Fumanelli L, Parlamento S, y Piontti AP, Dean NE, et al.
522 Containing Ebola at the source with ring vaccination. PLoS Negl Trop Dis.
523 2016;10: e0005093.
524 24. Thompson RN. Novel coronavirus outbreak in Wuhan, China, 2020: Intense
525 surveillance is vital for preventing sustained transmission in new locations. J Clin
526 Med. 2020;9: 498.
527 25. Fraser C. Estimating individual and household reproduction numbers in an
528 emerging epidemic. PLoS One. 2007;2: e758.
529 26. White LF, Moser CB, Thompson RN, Pagano M. Statistical estimation of the
530 reproductive number from case notification data. Am J Epidemiol. 2020; kwaa211.
531 27. Thompson RN, Stockwin JE, Gaalen RD Van, Polonsky JA, Kamvar ZN, Demarsh
532 PA, et al. Improved inference of time-varying reproduction numbers during
533 infectious disease outbreaks. Epidemics. 2019;19: 100356.
534 28. Isle of Man Government. COVID-19 Vaccination Programme. 2021 [cited 15 Apr

535 2021]. Available: https://covid19.gov.im/about-coronavirus/open-data-downloads/
536 29. Our World in Data. Coronavirus (COVID-19) vaccinations. 2021 [cited 23 Apr
537 2021]. Available: https://ourworldindata.org/covid-vaccinations
538 30. Bromiley J, Hart WS, Iwami S, Thompson RN. Assessing the threat from
539 emerging infectious diseases in seasonally varying environments. preprint. 2021.
540 31. Keeling MJ, Rohani P. Modeling infectious diseases in humans and animals.
541 Princeton University Press; 2008.
542 32. Thompson RN, Gilligan CA, Cunniffe NJ. Will an outbreak exceed available
543 resources for control? Estimating the risk from invading pathogens using practical
544 definitions of a severe epidemic. J R Soc Interface. 2020;17: 20200690.
545 33. Carmona P, Gandon S. Winter is coming: Pathogen emergence in seasonal
546 environments. PLoS Comput Biol. 2020;16: e1007954.
547 34. Ball FG. The threshold behaviour of epidemic models. J Appl Probab. 1983;20:
548 227–241.
549 35. Bacaër N, Ait Dads EH. On the probability of extinction in a periodic environment.
550 J Math Biol. 2014;68: 533–548.
551 36. Gillespie DT. Exact stochastic simulation of coupled chemical reactions. J Phys
552 Chem. 1977;8: 2340–2361.
553 37. Billah MA, Miah MM, Khan MN. Reproductive number of coronavirus: A
554 systematic review and meta-analysis based on global level evidence. PLoS One.
555 2020;15.
556 38. Kucharski AJ, Klepac P, Conlan AJK, Kissler SM, Tang ML, Fry H, et al.
557 Effectiveness of isolation, testing, contact tracing, and physical distancing on

558 reducing transmission of SARS-CoV-2 in different settings: a mathematical
559 modelling study. Lancet Infect Dis. 2020;20.
560 39. Centers for Disease Control and Prevention. Interim public health
561 recommendations for fully vaccinated people. 2021.
562 40. Sallam M. Covid-19 vaccine hesitancy worldwide: A concise systematic review of
563 vaccine acceptance rates. Vaccines. 2021.
564 41. Worldometer. Current world population. 2021 [cited 21 Apr 2021]. Available:
565 https://www.worldometers.info/world-population/
566 42. Isle of Man Government. Frequently asked questions about the vaccine. 2021.
567 43. Wise J. Covid-19: Pfizer BioNTech vaccine reduced cases by 94% in Israel,
568 shows peer reviewed study. BMJ. 2021;372.
569 44. Klein B, MacDonald PDM. The multitype continuous-time Markov branching
570 process in a periodic environment. Adv Appl Probab. 1980;12: 81–93.
571 45. Jagers P, Nerman O. Branching processes in periodically varying environment.
572 Ann Probab. 1985;13: 254–268.
573 46. Nipa KF, Allen LJS. Disease emergence in multi-patch stochastic epidemic
574 models with demographic and seasonal variability. Bull Math Biol. 2020;82: 152.
575 47. Bacaër N, Ed-Darraz A. On linear birth-and-death processes in a random
576 environment. J Math Biol. 2014;69: 73–90.
577 48. Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, et al. Feasibility
578 of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet
579 Glob Heal. 2020;8: E488-496.
580 49. Lovell-Read FA, Funk S, Obolski U, Donnelly CA, Thompson RN. Interventions

581 targeting non-symptomatic cases can be important to prevent local outbreaks:
582 SARS-CoV-2 as a case study. J R Soc Interface. 2021;18: 20201014.
583 50. Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd
584 immunity to SARS-CoV-2 infection by mass vaccination. The Lancet. 2020. p.
585 10263.
586 51. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the
587 transmission dynamics of SARS-CoV-2 through the postpandemic period.
588 Science (80-). 2020;368: 860–868.
589 52. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K-D, et al.
590 Impact of vaccination on SARS-CoV-2 cases in the community: a population-
591 based study using the UK's COVID-19 Infection Survey. medRxiv.
592 53. Gog JR, Hill EM, Danon L, Thompson RN. Vaccine escape in heterogeneous
593 populations: insights for SARS-CoV-2 from a simple model. medRxiv. 2021.
594 54. Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-
595 informed COVID-19 vaccine prioritization strategies by age and serostatus.
596 Science (80-). 2021;371.
597 55. Britton T, Ball F, Trapman P. A mathematical model reveals the influence of
598 population heterogeneity on herd immunity to SARS-CoV-2. Science (80-). 2020.
599 56. Davies NG, Klepac P, Liu Y, Prem K, Jit M, CMMID COVID-19 Working Group, et
600 al. Age-dependent effects in the transmission and control of COVID-19 epidemics.
601 Nat Med. 2020.
602 57. Thompson RN, Hollingsworth TD, Isham V, Arribas-Bel D, Ashby B, Britton T, et
603 al. Key questions for modelling COVID-19 exit strategies. Proc R Soc B Biol Sci.

604 2020;287: 20201405.

605 58. Sturrock HJ, Bennett AF, Midekisa A, Gosling RD, Gething PW, Greenhouse B.

606 Mapping malaria risk in low transmission settings: challenges and opportunities.

607 Trends Parasitol. 2016;32: 635–645.

608